CA
NZ
UK
AU
IND
US
Autolus Therapeutics plc (NASDAQ: AUTL) shares closed up 22% at $1.82 after the company disclosed preliminary second quarter 2026 financial results for AUCATZYL (obe-cel), featuring net product sales of approximately $45 million, a 70% sequential increase.
Inspire Medical Systems, Inc. (NYSE: INSP) shares are up 13% at $59.27 during extended hours even after the company revised its full-year 2026 GAAP EPS guidance downward to a range of $(0.42) to $0.17, a sharp reduction from its prior outlook of $0.07 to …
Genprex, Inc. (NASDAQ: GNPX) shares closed down 21% at $4.75 despite the company disclosing a tactical partnership with Roche Diagnostics aimed at validating TROP2 biomarker assay parameters to refine patient enrollment for clinical studies of REQORSA (quaratusugene ozeplasmid) in non-small cell lung cancer (NSCLC).
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) shares closed up 10% at $3.41 after the company announced a clinical safety update for the initial three patients treated under a modified protocol in its pivotal Phase 2 trial evaluating RP-A501, an investigational gene therapy for Danon disease.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares are up 82% at $0.51 during extended hours after the company announced that the USPTO has issued a Notice of Allowance for a new patent application titled "Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof."
● Bristol Myers Squibb (NYSE:BMY) is reportedly at the center of preliminary merger talks with AstraZeneca, a combination published reports value near $400 billion.
GeneDx Holdings (NASDAQ:WGS) shares are indicated up 7.66% in pre-market trading at $73.06, extending a 7.59% after-hours gain from Monday, after the company reported second-quarter results that beat Wall Street expectations across both revenue and earnings.
Rocket Pharmaceuticals (NASDAQ:RCKT) shares are indicated up 3.23% in pre-market trading at $3.52, building on a 9.65% gain in Monday's regular session, after the company announced a positive clinical safety update from its pivotal Phase 2 trial of RP-A501 for Danon disease.
SmartKem (NASDAQ:SMTK) shares are indicated down 15.27% in pre-market trading at $0.18, following the announcement that the company will merge with Ferrox Critical Minerals, a move aimed at strengthening SmartKem's critical minerals sourcing.
SRX Global (NYSE American: SRXH) shares are indicated up 3.06% in pre-market trading at $1.48, building on a 4.35% gain in Monday's regular session, as the company continues an active stake-building strategy across several small-cap holdings.
Please wait processing your request...